(Q34355597)

1 August 2017

1 reference

title

Bispecific and bifunctional single chain recombinant antibodies (English)

1 reference

1 August 2017

1 reference

Kriangkum J

1

1 reference

1 August 2017

Xu B

2

1 reference

1 August 2017

Nagata LP

3

1 reference

1 August 2017

Fulton RE

4

1 reference

1 August 2017

Suresh MR

5

1 reference

1 August 2017

1 September 2001

1 reference

1 August 2017

1 reference

1 August 2017

18

1 reference

1 August 2017

2

1 reference

1 August 2017

31-40

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

1 reference

7 January 2021

New protein engineering approaches to multivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Bispecific monoclonal antibodies from hybrid hybridomas

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Recombinant antibody constructs in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

"Diabodies": small bivalent and bispecific antibody fragments

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

High avidity scFv multimers; diabodies and triabodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

An efficient route to human bispecific IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Remodeling domain interfaces to enhance heterodimer formation

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Inter-active-site distance and solution dynamics of a bivalent-bispecific single-chain antibody molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Development of a functional monoclonal single-chain variable fragment antibody against Venezuelan equine encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A single chain Fv specific against Western equine encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A dimeric bispecific miniantibody combines two specificities with avidity

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

An efficient route to the production of an IgG-like bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Applications of a peptide ligand for streptavidin: the Strep-tag.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Construction and characterization of a novel recombinant single-chain variable fragment antibody against Western equine encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Expression of an antibody fragment at high levels in the bacterial cytoplasm.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Immunotoxins in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Recombinant single-chain Fv antibody fragment-alkaline phosphatase conjugate for one-step immunodetection in molecular hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Bifunctional fusion proteins consisting of a single-chain antibody and an engineered lanthanide-binding protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1389-0344%2801%2900083-1

7 January 2021

10.1016/S1389-0344(01)00083-1

Identifiers

DOI

1 reference

1 August 2017

1 reference